News and Comments

A Judge is Offended About False Claims Against Gilead. Good News from Regeneron

  Monday, May 02, 2016

GILEAD SCIENCES More...

The FDA Approval of Exelixis Drug Cabometyx™ Is Indeed Great News

  Tuesday, April 26, 2016

Congratulation.   More...

Nectar Therapeutics and Seattle Genetics at the AACR Meeting

  Tuesday, April 19, 2016

Meaningful Presentations  More...

Good News from Juno Therapeutics and from Abbvie. Disappointing News for Clovis Oncology

  Wednesday, April 13, 2016

Juno Therapeutics (JUNO) is due to receive a fee payment of $50 million from Celgene. The reason for this compensation is that Celgene has exercised its option to develop and commercialize Juno CD19 program outside North America and China.  More...

Theravance Biopharma Drug Vibativ Overcomes Serious Infections. See Also Juno Therapeutics In China

  Monday, April 11, 2016

Dealing With Bacterial Resistance To Antibiotics    More...

Human Longevity Firm Aims at Bringing the Missing Full Picture of Human Health

  Thursday, April 07, 2016

  More...

Gilead's Well Chosen New Acquisition Is Not the Last, It Is Just the Beginning

  Monday, April 04, 2016

Many in Wall Street have been anxious, sitting on fire while waiting to learn, which biotech company Gilead Sciences (GILD) would decide upon acquiring that would deepen and enhance its pipeline. In Today’s news, a firm called Nimbus Therapeutics, LLC today announced that it has signed a definitive agreement under which terms Gilead will acquire Nimbus Apollo, Inc., a Nimbus Therapeutics wholly-owned subsidiary. Important is that the acquisition includes the firm’s Acetyl-CoA Carboxylase (ACC) inhibitor program. The cost, which is around $1.2 billion will be given in an upfront payment of $400 million and an additional $800 million in development-related milestones over time. More...

Alder Biopharmaceutical Migraine Headache Drug Passes the Test. Our Voting Regarding Acadia Drug Nuplazid Approval

  Monday, March 28, 2016

Alder Reports Phase 2b Trial of ALD403 Meets Primary and Secondary Endpoints Demonstrating Migraine Prevention in Patients with Chronic Migraine More...

Vitae Pharmaceuticals: Opening a New Door Towards the Management of Psoriasis. The Drug Could Be Great for Many Other Autoimmune Diseases.

  Thursday, March 17, 2016

Published articles in peer review journals cited that pharmacologic inhibition of RORγt regulates Th17 signature gene expression and suppresses cutaneous inflammation in vivo. Here we are, a clinical stage small company called Vitae Pharmaceuticals (VTAE) has just announced positive results from its Phase 2a proof-of-concept clinical trial of its RORyt inhibitor drug VTP-43742 in psoriatic patients.  More...

GW Pharmaceuticals: A Cannabinoid Product Succeeds in Treating a Resistant Epilepsy. Stock Price Doubled.

  Monday, March 14, 2016

London, UK; 14 March 2016:  GW Pharmaceuticals (GWPH), is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform. The firm announced the positive results of the first pivotal Phase 3 study of its investigational medicine Epidiolex® (cannabidiol or CBD) for the treatment of Dravet syndrome. In this study, the firm’s product, Epidiolex, achieved the primary endpoint of a significant reduction in convulsive seizures assessed over the entire treatment period compared with placebo (p=0.01).  More...


Recent Postings


Archive


Tags

Idenix (IDIX) Alnylam (ALNY) Human Genome Sciences (HGSI) Anacor (ANAC) Gilead (GILD) Agenus (AGEN CompuGen (CGEN) Intermune (ITMN) Intercept (ICPT) ADVENTRIX (ANX) Abbott Laboratories (ABT) C4 Therapeutics Roche (ROCHE) Sangamo (SGMO) Auspex (ASPX) Cytokinetics (CYTK) SYNTA (SNTA) Bristol-Myers Squibb (BMY) GUARDIAN HEALTH INNOVIVA (INVA) AGOS (ARGS) Alder Biopharmaceuticals (ALDR) Trastuzumab-DM1 Prosensa (RNA) Xoma (XOMA) REGULUS (RGLS) HALOZYME (HALO) Mirati Therapeutics (MRTX) Vitae Pharmaceuticals (VTAE) Benlysta (belimumab) Ariad (ARIA) Jazz Pharmaceuticals (JAZZ) Roche (RHHBY) Rapamune KERYX (KERX) Merck (MRK) Biogen Idec (BIIB) Tysabri Multiple Myeloma Ridaforolimus Onyx (ONXX) Illumina (ILMN) SERES THERAPEUTICS (MCRB) ABBVIE (ABBV) ARCA (ABIO) Elan (ELN) Human Longevity (HLI) PTC Therapeutics (PTCT) Sequenom (SQNM) Regeneron (REGN) Global Cell Therapeutics (GBT) ACADIA (ACAD) Revlimid (lenolidamide) Inovio (INO) Ziofpharm (ZIOP) Anadys (ANDS) Genentech ImmunoGen (IMGN) NANTKWEST (NK) RenenxBio (RGNX) Micromet (MITI) SUNESIS PHARMACEUTICALS (SNSS) ZALTRAP™ Valeant Pharmaceuticals International (VRX) Biocryst (BCRX) VANDA (VNDA) KITE (KITE) TOKAI (TKAOI) Sanofi (SNA) Incyte (INCY) Sanofi-Aventis (SAN) GlaxoSmithKline (GSK) Seattle Genetics (SGEN) Herceptin Endometrial Cancer Array Pharmaceuticals (ARRY) Theravance Bio Pharma (TBPH) Sarepta (SRPT) Editas (EDIT) BIOMARIN (BMRN) Velcade (bortezomib) OSI (OSIP) Agenus (AGEN) Prolor Biotech (PBTH) Ionis (IONS) Theravance (THRX) Dynavax (DVAX) Amgen (AMGN) ARGOS (ARGS) galapagos (GLPG) Galena (GALE) Sanofi (SNY) Spike Therapeutics (ONCE) Aimmune Therapeutics (AIMT) Telaprevir JUNO (JUNO) IDERA (IDRA) ISIS (ISIS) Vertex (VRTX) Pluristem (PSTI) Intrexon (XON) NEKTAR (NKTR)) Exelixis (EXEL) AERIE PHARMACEUTICALS Dendreon (DNDN) Zerenex